Patent ID: 7919607

Claim:
A nucleic acid molecule encoding a humanized CC49 antibody, wherein the humanized CC49 antibody comprises: four variable light framework regions and four variable heavy framework regions of a human antibody; a light chain complementarity determining region (L-CDR)1, a L-CDR2, a L-CDR3, a heavy chain complementarity determining region (H-CDR)1, a H-CDR2, and a H-CDR3; a non-conservative substitution of a first residue, wherein the first residue is in the L-CDR3 of the antibody and wherein the non-conservative substitution of the first residue is at position 91 and is a tyrosine to proline substitution; and a substitution of a second residue, wherein the substitution of the second residue is at position 27b and is a valine to leucine substitution; wherein the L-CDR1, L-CDR2, L-CDR3, H-CDR1, H-CDR2, and H-CDR3 are the parent HuCC49V10 antibody L-CDR1, L-CDR2, L-CDR3, H-CDR1, H-CDR2, and H-CDR3, respectively, and the humanized CC49 antibody has a high binding affinity for TAG-72 and is minimally immunogenic, compared to HuCC49V10, deposited as ATCC Accession No. PTA-5416.